Sun Pharmaceutical Industries Ltd vs Unjha Formulations Ltd

A side-by-side comparison of Sun Pharmaceutical Industries Ltd (SUNPHARMA) and Unjha Formulations Ltd (UNJHAFOR) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Ltd leads SUNPHARMA vs UNJHAFOR on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

41.01
P/E ratio
26.64
5.60
P/B ratio
3.03
0.82%
Dividend yield
0.00%
₹47.84
EPS
₹0.92

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.00%
Return on equity
12.98%
21.00%
Return on capital
18.06%
30.00%
EBITDA margin
3.75%
19.69%
Net margin
2.96%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.03%
Revenue CAGR (3Y)
5.84%
10.57%
Profit CAGR (3Y)
35.07%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹4.67L Cr
Market cap
₹12 Cr
₹58,462 Cr
Revenue
₹14 Cr
₹11,509 Cr
Net profit
₹0 Cr
0.06
Debt / equity
0.00
Sun Pharmaceutical Industries Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Unjha Formulations Ltd
  • + ["Company is almost debt free."]
  • ["The company has delivered a poor sales growth of 9.60% over past five years.", "Promoter holding is low: 36.9%"]
Sun Pharmaceutical Industries Ltd full analysis Unjha Formulations Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.